...
首页> 外文期刊>The American Journal of Surgery >Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma
【24h】

Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma

机译:实体瘤反应评估标准与容积测量法在评估胰腺腺癌和肝细胞癌肿瘤负荷方面的比较

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Response evaluation criteria in solid tumors (RECIST) is the accepted method for determining tumor progression. However, RECIST may not estimate disease burden accurately because the axial plane often does not produce the actual longest diameter. Volumetric measurements may be an alternative to better determine tumor size. Our aim was to compare volumetric measurements with RECIST in pancreatic ductal adenocarcinomas (PDA) and hepatocellular carcinomas (HCC). Methods: RECIST and volumetric measurements were determined in 9 patients with metastatic PDA and 17 patients with HCC who subsequently underwent liver transplantation. Gross pathologic measurements after hepatectomy also were analyzed for volumes. Results: Three-dimensional diameter in volumetric analysis was 38% and 36% higher than RECIST diameter in PDA and HCC, respectively (P <.01). However, RECIST yielded 78% and 23% larger estimated tumor volumes than volumetric analysis in PDA and HCC, respectively (P <.01). Gross pathologic volume in HCC showed a linear correlation with both volumetric analysis (r =.95; P <.01) and RECIST (r =.96; P <.01) but RECIST significantly overestimated gross pathologic volume by an average of 28% (P <.01) whereas volumetric analysis was similar to gross pathologic volume (P =.56). In categorizing treatment response in PDA, RECIST and volumetric analysis were in moderate agreement (κ =.49). Conclusions: RECIST significantly may overestimate tumor burden compared with volumetric measurements in both PDA and HCC. Volumetric analysis may be the preferred method to detect tumor progression.
机译:背景:实体瘤反应评估标准(RECIST)是确定肿瘤进展的公认方法。但是,RECIST可能无法准确估算疾病负担,因为轴向平面通常不会产生实际最长的直径。体积测量可能是更好地确定肿瘤大小的替代方法。我们的目的是比较RECIST在胰腺导管腺癌(PDA)和肝细胞癌(HCC)中的体积测量。方法:对9例转移性PDA患者和17例HCC患者,随后进行肝移植进行了RECIST和体积测量。还分析了肝切除术后的总体病理测量结果。结果:体积分析中的三维直径分别比PDA和HCC中的RECIST直径高38%和36%(P <.01)。但是,RECIST产生的估计肿瘤体积比PDA和HCC中的体积分析分别大78%和23%(P <.01)。肝癌的总病理体积与体积分析(r = .95; P <.01)和RECIST(r = .96; P <.01)均呈线性相关,但RECIST显着高估了总病理体积平均28% (P <.01),而体积分析与病理总体积相似(P = .56)。在对PDA中的治疗反应进行分类时,RECIST和体积分析结果一致(κ= .49)。结论:与PDA和HCC中的体积测量相比,RECIST可能显着高估了肿瘤负担。体积分析可能是检测肿瘤进展的首选方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号